Martin Fredrich Stefanic

Title: Martin Fredrich Stefanic: Innovator in Immunologic Treatments

Introduction

Martin Fredrich Stefanic is a notable inventor based in Munich, Germany. He has made significant contributions to the field of immunology through his innovative research and development of therapeutic methods.

Latest Patents

Stefanic holds a patent for the "Use of Lck inhibitors for treatment of immunologic diseases." This invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component. It utilizes certain Lck inhibitors, which are already known as kinase inhibitors for therapy in oncology. The patent also discusses the potential use of these inhibitors in combination with other drugs, including NSAIDs, steroids, DMARDs, immunosuppressives, biologic response modifiers, and anti-infectives. The pharmaceutical compositions comprising these Lck inhibitors, along with the other drugs, are designed for the treatment of immunologic diseases or conditions.

Career Highlights

Martin Fredrich Stefanic is currently employed at Boehringer Ingelheim Pharma GmbH & Co. KG, where he continues to advance his research in immunologic therapies. His work has been instrumental in developing new treatment options for patients suffering from various immunologic diseases.

Collaborations

Stefanic has collaborated with esteemed colleagues such as Gerald Juergen Roth and Armin Heckel. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries in the field.

Conclusion

Martin Fredrich Stefanic is a prominent figure in the realm of immunologic treatments, with a focus on utilizing Lck inhibitors for therapeutic purposes. His contributions to the field are paving the way for new and effective treatment options for immunologic diseases.